No. 30, Keya Road
4th Floor Daya District
Taichung
Taiwan
886 4 2325 2888
https://www.ever-supreme.com.tw
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was incorporated in 2016 and is based in Taichung, Taiwan.
L’ISS Governance QualityScore de Ever Supreme Bio Technology Co., Ltd en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..